Literature DB >> 9688447

The changing pattern of infection in neutropenic patients.

B A Oppenheim1.   

Abstract

Over the past 20 years there has been a dramatic shift in the pattern of infection in neutropenic patients. During the 1970s Gram-negative organisms caused approximately 70% of all bacteraemias, but by the late 1980s the situation had reversed and approximately 70% of bacteraemias were due to Gram-positive organisms. The main contributors to this increase in Gram-positive infections have been the coagulase-negative staphylococci and the viridans streptococci. More recently, enterococci have emerged as significant pathogens in this patient group, and the development of glycopeptide resistance in the enterococci is of particular concern since this class of antibiotics is widely used in neutropenic patients. Among Gram-negative organisms, the emergence of resistance to fluoroquinolones, particularly in Escherichia coli, is a worrying feature which may lead to a reassessment of the use of quinolone prophylaxis in this setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688447     DOI: 10.1093/jac/41.suppl_4.7

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Microbial etiology of febrile neutropenia.

Authors:  Mudshingkar Swati; Nataraj Gita; Baveja Sujata; Jijina Farah; Mehta Preeti
Journal:  Indian J Hematol Blood Transfus       Date:  2010-09-30       Impact factor: 0.900

2.  Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.

Authors:  H Giamarellou; H P Bassaris; G Petrikkos; W Busch; M Voulgarelis; A Antoniadou; E Grouzi; N Zoumbos
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

3.  Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.

Authors:  Karin Mayer; Corinna Hahn-Ast; Sara Mückter; Andrea Schmitz; Simon Krause; Linda Felder; Isabelle Bekeredjian-Ding; Ernst Molitor; Peter Brossart; Marie von Lilienfeld-Toal
Journal:  Support Care Cancer       Date:  2015-01-24       Impact factor: 3.603

4.  Infection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patients.

Authors:  Eleni Apostolopoulou; Vasilios Raftopoulos; Konstantinos Terzis; Ioannis Elefsiniotis
Journal:  BMC Infect Dis       Date:  2010-05-26       Impact factor: 3.090

5.  Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey.

Authors:  Selda Aslan; Elvan Caglar Citak; Reyhan Yis; Suleyman Degirmenci; Dilek Arman
Journal:  Indian J Microbiol       Date:  2011-08-13       Impact factor: 2.461

6.  Bacterial infection profiles in lung cancer patients with febrile neutropenia.

Authors:  Jean-Philippe Lanoix; Emilie Pluquet; Francois Xavier Lescure; Houcine Bentayeb; Emmanuelle Lecuyer; Marie Boutemy; Patrick Dumont; Vincent Jounieaux; Jean Luc Schmit; Charles Dayen; Youcef Douadi
Journal:  BMC Infect Dis       Date:  2011-06-27       Impact factor: 3.090

7.  Genetic relatedness and risk factor analysis of ampicillin-resistant and high-level gentamicin-resistant enterococci causing bloodstream infections in Tanzanian children.

Authors:  Håvard Aamodt; Stein Christian Mohn; Samuel Maselle; Karim P Manji; Rob Willems; Roland Jureen; Nina Langeland; Bjørn Blomberg
Journal:  BMC Infect Dis       Date:  2015-02-28       Impact factor: 3.090

8.  Microbial spectrum and drug-resistance profile of isolates causing bloodstream infections in febrile cancer patients at a referral hospital in Addis Ababa, Ethiopia.

Authors:  Balew Arega; Yimtubezinash Woldeamanuel; Kelemework Adane; Abdulaziz A Sherif; Daniel Asrat
Journal:  Infect Drug Resist       Date:  2018-09-18       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.